Bronchodilatory effect of inhaled budesonide/formoterol and budesonide/salbutamol in acute asthma: a double-blind, randomized controlled trial

BMC Pediatrics

Sushil K Kabra¹  Rakesh Lodha¹  Jenish J Arun¹ 

[1] Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, Ansari Nagar 110029, India

关键词: Salbutamol;    Formoterol;    Bronchodilatation;    Acute asthma;   

Others  :  1178926
DOI  :  10.1186/1471-2431-12-21

 received in 2011-03-10, accepted in 2012-03-07,  发布年份 2012

【 摘 要 】

Background

There are no published studies that have compared bronchodilatory effect of inhaled budesonide/formoterol combination with budesonide/salbutamol delivered by metered dose inhaler with a spacer in acute exacerbation of asthma in children. We, therefore, compared the bronchodilatory effects of inhaled budesonide/formoterol (dose: 200 μg and 12 μg respectively) combination with budesonide (200 μg)/salbutamol (200 μg) administered by metered dose inhaler and spacer in children of 5-15 years with mild acute exacerbation of asthma [Modified Pulmonary Index Score (MPIS) between 6-8] in this double-blind, randomized controlled trial. The primary outcome was FEV1 (% predicted) in the two groups at 1, 5, 15, 30, 60 min after administration of the study drug.

Results

We did not observe any significant differences in the % predicted FEV1 and MPIS between formoterol and salbutamol at various time points from 1 min to 60 min post drug administration. There was significant improvement in FEV1 (% predicted) from baseline in both the groups as early as 1 min after drug administration.

Conclusions

Salbutamol or formoterol delivered along with inhaled corticosteroid by metered dose inhaler with spacer in children between 5-15 years of age with mild acute exacerbation of asthma had similar bronchodilatory effects.

Trial Registration

ClinicalTrials.gov: NCT00900874

【 授权许可】

   
2012 Arun et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]National Asthma Education and Prevention Program: Expert panel report 2. Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes Of Health; 1991. Publication no.97-4051
• [2]Jindal SK, Gupta D, Aggarwal AN, Agarwal R: Guidelines for management of asthma at primary and secondary levels of health care in India- a consensus statement developed under WHO- government of India collaborative programme (2004-2005). Indian J Chest Dis Allied Sci 2005, 47:309-343.
• [3]Berger WE: The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol 2006, 97:24-33.
• [4]Rodrigo GJ, Neffen H, Colodenco FD, Castro-Rodriguez JA: Formoterol for acute asthma in the emergency department: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2010, 104:247-252.
• [5]Welsh EJ, Cates CJ: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma. Cochrane Database Syst Rev 2010, 8(9):CD008418.
• [6]Avila-Castañón L, Casas-Becerra B, Del Río-Navarro BE, Velázquez-Armenta Y, Sienra-Monge JJ: Formoterol vs. albuterol administered via Turbuhaler system in the emergency treatment of acute asthma in children. Allergol Immunopathol (Madr) 2004, 32:18-20.
• [7]Rodriguez E, Vera V, Perez-Puigbo A, Capriles-Hulett A, Ferro S, Manrique J, Abate J: Equivalence of a single saline nebulised dose of formoterol powder vs three doses of nebulised Albuterol every twenty minutes in acute asthma in children: a suitable cost effective approach for developing nations. Allergol Immunopathol (Madr) 2008, 36:196-200.
• [8]Bussamra MH, Stelmach R, Rodrigues JC, Cukier A: A randomized, comparative study of formoterol and terbutaline dry powder inhalers in the treatment of mild to moderate asthma exacerbations in the pediatric acute care setting. Ann Allergy Asthma Immunol 2009, 103:248-253.
• [9]Carroll CL, Sekaran AK, Lerer TJ, et al.: A modified pulmonary index score with predictive value for pediatric asthma exacerbations. Ann Allergy Asthma Immunol 2005, 94:355-359.
• [10]Sealed Envelope Ltd. Power (sample size) calculators [http://www.sealedenvelope.com/power.php] webcite
• [11]Boonsawat W, Charoenratanakul S, Pothirat C, et al.: Formoterol (OXIS) Turbuhaler® as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med 2003, 97:1067-1074.
• [12]Najafizadeh K, Sohrab Pour H, Ghadyanee M, Shiehmorteza M, Jamali M, Majdzadeh S: A randomised, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma. Emerg Med J 2007, 24:317-321.
• [13]Lee-Wong M, Chou V, Ogawa Y: Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting. Ann Allergy Asthma Immunol 2008, 100:146-152.
• [14]Singhania N, Dhamija R, Lodha R, Kabra SK: Salmeterol vs. Formoterol: A comparison of rapid bronchodilator effect in a randomized controlled trial. Indian Pediatr 2008, 45:225-228.
• [15]Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention [http:/ / www.ginasthma.org/ guidelines-gina-report-global-strat egy-for-asthma.html] webcite 2008.
• [16]Haney S, Hancox RJ: Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial. Respir Res 2005, 6:107. BioMed Central Full Text
• [17]Cates CJ, Lasserson TJ: Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2010, 1:CD007694.